HMGA1 protein is a novel target of the ATM kinase

European Journal of Cancer

Volumn 44, Issue 17, 2008, Pages 2668-2679

  Pentimalli, Francesca ^a,b   Palmieri, Dario ^a   Pacelli, Roberto ^c   Garbi, Corrado ^a   Cesari, Rossano ^b,d   Martin, Eric ^b,e   Pierantoni, Giovanna Maria ^a   Chieffi, Paolo ^f   Croce, Carlo Maria ^g   Costanzo, Vincenzo ^a,h   Fedele, Monica ^a   Fusco, Alfredo ^a,i  

^a CNR   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CNR   (Italy)

^d SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h London Research Institute   (United Kingdom)

ⁱ CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

ATM; DNA damage; HMGA1

Indexed keywords

ATM PROTEIN; GLUTAMINE; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1B PROTEIN; SERINE;

AMINO ACID SEQUENCE; ARTICLE; CELL ACTIVITY; CELL CYCLE; CELL STRAIN MCF 7; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME REARRANGEMENT; CLONOGENESIS; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DOWNSTREAM PROCESSING; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA-BINDING PROTEINS; HMGA1A PROTEIN; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RADIATION, IONIZING; TUMOR SUPPRESSOR PROTEINS;

EID: 55549146787     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.033     Document Type: Article

References (41)

1. Reeves R., and Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519 (2001) 13-29
2. Martinez Hoyos J., Fedele M., Battista S., et al. Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. Cancer Res 64 (2004) 5728-5735
3. Chiappetta G., Avantaggiato V., Visconti R., et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13 (1996) 2439-2446
4. Chiappetta G., Tallini G., De Biasio M.C., et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58 (1998) 4193-4198
5. Baldassarre G., Battista S., Belletti B., et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol 23 (2003) 2225-2238
6. Masciullo V., Baldassarre G., Pentimalli F., et al. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24 (2003) 1191-1198
7. Tamimi Y., van der Poel H.G., Denyn M.M., et al. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 53 (1993) 5512-5516
8. Berlingieri M.T., Pierantoni G.M., Giancotti V., Santoro M., and Fusco A. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21 (2002) 2971-2980
9. Scala S., Portella G., Fedele M., Chiappetta G., and Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 97 (2000) 4256-4261
10. Wood L.J., Maher J.F., Bunton T.E., and Resar L.M. The oncogenic properties of the HMG-I gene family. Cancer Res 60 (2000) 4256-4261
11. Reeves R., Edberg D.D., and Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 21 (2001) 575-594
12. Baldassarre G., Belletti B., Battista S., et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene 24 (2005) 6809-6819
13. Fedele M., Pentimalli F., Baldassarre G., et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24 (2005) 3427-3435
14. Takaha N., Hawkins A.L., Griffin C.A., Isaacs W.B., and Coffey D.S. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res 62 (2002) 647-651
15. Scully R., and Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408 (2000) 429-432
16. Adair J.E., Kwon Y., Dement G.A., Smerdon M.J., and Reeves R. Inhibition of nucleotide excision repair by high mobility group protein HMGA1. J Biol Chem 280 (2005) 32184-32192
17. Boo L.M., Lin H.H., Chung V., et al. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 65 (2005) 6622-6630
18. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3 (2003) 155-168
19. Savitsky K., Bar-Shira A., Gilad S., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 (1995) 1749-1753
20. McKinnon P.J. ATM and ataxia telangiectasia. EMBO Rep 5 (2004) 772-776
21. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
22. O'Neill T., Dwyer A.J., Ziv Y., et al. Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem 275 (2000) 22719-22727
23. Battista S., Pentimalli F., Baldassarre G., et al. Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J 11 (2003) 1496-1498
24. Pierantoni G.M., Fedele M., Pentimalli F., et al. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 43 (2001) 6132-6141
25. Canman C.E., Lim D.S., Cimprich K.A., et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 (1998) 1677-1679
26. Edberg D.D., Bruce J.E., Siems W.F., and Reeves R. In vivo posttranslational modifications of the high mobility group A1a proteins in breast cancer cells of differing metastatic potential. Biochemistry 43 (2004) 11500-11515
27. Sgarra R., Rustighi A., Tessari M.A., et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 574 (2004) 1-8
28. Zou Y., and Wang Y. Tandem mass spectrometry for the examination of the posttranslational modifications of high-mobility group A1 proteins: symmetric and asymmetric dimethylation of Arg25 in HMGA1a protein. Biochemistry 44 (2005) 6293-6301
29. Sarkaria J.N., Busby E.C., Tibbetts R.S., et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59 (1999) 4375-4382
30. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., and Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273 (1998) 5858-5868
31. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., and Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10 (2000) 886-895
32. Jazayeri A., Falck J., Lukas C., et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 8 (2006) 37-45
33. Falck J., Coates J., and Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434 (2005) 605-611
34. Lee J.H., and Paull T.T. ATM activation by DNA double-strand breaks through the Mre11/Rad50/Nbs1 complex. Science 308 (2005) 551-554
35. You Z., Chahwan C., Bailis J., Hunter T., and Russell P. ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1. Mol Cell Biol 25 (2005) 5363-5379
36. Lou Z., Minter-Dykhouse K., Franco S., et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 21 (2006) 187-200
37. Fernandez-Capetillo O., Chen H.T., Celeste A., et al. DNA damage-induced G2-M checkpoint activation by histone H2Ax and 53BP1. Nat Cell Biol 4 (2002) 993-997
38. Stewart G.S., Wang B., Bignell C.R., Taylor A.M., and Elledge S.J. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421 (2003) 961-966
39. Gatei M., Sloper K., Sorensen C., et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278 (2003) 14806-14811
40. Hirao A., Cheung A., Duncan G., et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22 (2002) 6521-6532
41. Takai H., Naka K., Okada Y., et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. Embo J 21 (2002) 5195-5205